Results 11 to 20 of about 4,565 (213)

An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam [PDF]

Infectious Diseases and Therapy, 2020
Plain Language Summary Carbapenem-resistant gram-negative pathogens, specifically, Enterobacteriaceae, remain an urgent public health threat, and safe, effective treatment options are limited. The antibiotic agents meropenem and vaborbactam were selected
Eric Wenzler, Patrick J. Scoble
doaj   +3 more sources

NCY‐1 β‐Lactamase Activity Correlates With Antimicrobial Susceptibility of a Clinical Strain of Nocardia cyriacigeorgica

MicrobiologyOpen
Nocardiosis is an infectious disease caused by several Nocardia species, among which Nocardia cyriacigeorgica is one of the most frequently isolated species in the clinic.
Julie Couston, Athénaïs Le Marchand, Elisabeth Hodille, Charlotte Genestet, Brune Joannard, Jérôme Feuillard, Yvonne Benito, Oana Dumitrescu, Mickaël Blaise   +8 more
doaj   +2 more sources

Biochemical Activity of Vaborbactam [PDF]

Antimicrobial Agents and Chemotherapy, 2020
The most common mechanism of resistance to β-lactams antibiotics in Gram-negative bacteria is production of β-lactamase enzymes capable of cleaving the β-lactam ring. Inhibition of β-lactamase activity with small-molecule drugs is a proven strategy to restore the potency of many β-lactam antibiotics.
Tsivkovski, Ruslan, Lomovskaya, Olga
openaire   +2 more sources

Evaluation with E-test of the meropenem/vaborbactam association in carbapenem-resistant and sensitive negative control strains isolates of samples processed at the Laboratory of the Rivoli Hospital

Microbiologia Medica, 2022
Background and aims: Meropenem (Mer) and vaborbactam (Vab) is a combination of a carbapenem and a new β-lactamase inhibitor used in adults to treat different types of infections caused by Gram-negative bacteria.
Giuseppina Amarù, Lara Scoppapietra, Cristina Crocillà, Marika Salafia, Mara Finotti, Vittorio Schiavo, Valentino Granero   +6 more
doaj   +1 more source

Vaborbactam increases meropenem susceptibility in Pseudomonas aeruginosa clinical isolates displaying MexXY and AmpC upregulation

mSphere, 2023
To evaluate the resistance mechanisms among Pseudomonas aeruginosa clinical isolates exhibiting meropenem (MEM) MIC values higher than meropenem-vaborbactam (MEV). P.
Mariana Castanheira, Timothy B. Doyle, Cory M. Hubler, Sean DeVries, Dee Shortridge   +4 more
doaj   +1 more source

Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors

Antibiotics, 2021
The growing emergence of drug-resistant bacterial strains is an issue to treat severe infections, and many efforts have identified new pharmacological agents.
Giacomo Luci, Francesca Mattioli, Marco Falcone, Antonello Di Paolo   +3 more
doaj   +1 more source

Outcomes and Predictors of Mortality in Patients With KPC-Kp Infections Treated With Meropenem Vaborbactam: An Observational Multicenter Study [PDF]

Background Meropenem-vaborbactam is a recent and promising option for the treatment of KPC-producing Klebsiella pneumoniae (KPC-Kp) infections, including those resistant to ceftazidime-avibactam.Methods We conducted a retrospective analysis of ...
Corcione, Silvia, De Benedetto, Ilaria, De Rosa, Francesco Giuseppe   +2 more
core   +15 more sources

Fast and Sensitive Method for Simultaneous Quantification of Meropenem and Vaborbactam in Human Plasma Microsamples by Liquid Chromatography–Tandem Mass Spectrometry for Therapeutic Drug Monitoring

Antibiotics, 2023
Meropenem (MRP)-Vaborbactam (VBR) is a novel beta-lactam/beta-lactamase inhibitor used for the management of difficult-to-treat Gram-negative infections.
Rossella Barone, Matteo Conti, Beatrice Giorgi, Milo Gatti, Pier Giorgio Cojutti, Pierluigi Viale, Federico Pea   +6 more
doaj   +1 more source

Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance

Antibiotics, 2023
Due to the fact that there is a steadily increasing trend in the area of antimicrobial resistance in microorganisms, there is a need to look for new treatment alternatives.
Anna Duda-Madej, Szymon Viscardi, Ewa Topola   +2 more
doaj   +1 more source

Potency of Meropenem-Vaborbactam in Lung Surfactant [PDF]

Antimicrobial Agents and Chemotherapy, 2018
ABSTRACT This study investigated whether pulmonary surfactant has an effect on the in vitro antibacterial activity of either meropenem alone or meropenem in combination with vaborbactam at a fixed concentration of 8 μg/ml against several Klebsiella pneumoniae carbapenemase (KPC ...
Debora, Rubio-Aparicio, Jeff, Loutit, Michael, Dudley, Olga, Lomovskaya   +3 more
openaire   +2 more sources